Literature DB >> 28881919

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M Dreyling1, E Campo2, O Hermine3, M Jerkeman4, S Le Gouill5, S Rule6, O Shpilberg7, J Walewski8, M Ladetto9.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28881919     DOI： 10.1093/annonc/mdx223

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  59 in total

1.  Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Authors:  Andres Forero-Torres; Radhakrishnan Ramchandren; Abdulraheem Yacoub; Michael S Wertheim; William J Edenfield; Paolo Caimi; Martin Gutierrez; Luke Akard; Carolina Escobar; Justin Call; Daniel Persky; Swaminathan Iyer; Douglas J DeMarini; Li Zhou; Xuejun Chen; Fitzroy Dawkins; Tycel J Phillips
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

2.  Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series.

Authors:  Alberto Fabbri; Emanuele Cencini; Angela Giovanna Congiu; Maurizio Miglino; Luigi Rigacci; Monica Bocchia
Journal:  Am J Blood Res       Date:  2020-12-15

3.  Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.

Authors:  Clément Bailly; Thomas Carlier; Alina Berriolo-Riedinger; Olivier Casasnovas; Emmanuel Gyan; Michel Meignan; Anne Moreau; Barbara Burroni; Loïc Djaileb; Remy Gressin; Anne Devillers; Thierry Lamy; Catherine Thieblemont; Olivier Hermine; Françoise Kraeber-Bodéré; Steven Le Gouill; Caroline Bodet-Milin
Journal:  Haematologica       Date:  2019-08-01       Impact factor: 9.941

4.  Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.

Authors:  Simon Rule; Martin Dreyling; Andre Goy; Georg Hess; Rebecca Auer; Brad Kahl; José-Ángel Hernández-Rivas; Keqin Qi; Sanjay Deshpande; Lori Parisi; Michael Wang
Journal:  Haematologica       Date:  2018-11-15       Impact factor: 9.941

5.  Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.

Authors:  Hilka Rauert-Wunderlich; Anja Mottok; David W Scott; Lisa M Rimsza; German Ott; Wolfram Klapper; Michael Unterhalt; Hanneke C Kluin-Nelemans; Olivier Hermine; Sylvia Hartmann; Christoph Thorns; Grzegorz Rymkiewicz; Harald Holte; Martin Dreyling; Eva Hoster; Andreas Rosenwald
Journal:  Br J Haematol       Date:  2018-08-10       Impact factor: 6.998

Review 6.  Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.

Authors:  Adalgisa Condoluci; Davide Rossi; Emanuele Zucca; Franco Cavalli
Journal:  Curr Oncol Rep       Date:  2018-08-22       Impact factor: 5.075

Review 7.  Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.

Authors:  Danielle Wallace; Patrick M Reagan
Journal:  Drugs       Date:  2021-03-30       Impact factor: 9.546

8.  The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.

Authors:  Lorenz Selberg; Peter Stadtherr; Sascha Dietrich; T Hien Tran; Thomas Luft; Ute Hegenbart; Andrea Bondong; Julia Meissner; Nora Liebers; Michael Schmitt; Anthony Dick Ho; Carsten Müller-Tidow; Peter Dreger
Journal:  Bone Marrow Transplant       Date:  2020-06-18       Impact factor: 5.483

9.  Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).

Authors:  Vittorio Stefoni; Cinzia Pellegrini; Alessandro Broccoli; Luca Baldini; Monica Tani; Emanuele Cencini; Amalia Figuera; Michela Ansuinelli; Elisa Bernocco; Maria Cantonetti; Maria Christina Cox; Filippo Ballerini; Chiara Rusconi; Carlo Visco; Luca Arcaini; Angelo Fama; Roberto Marasca; Stefano Volpetti; Alessia Castellino; Catello Califano; Marina Cavaliere; Guido Gini; Anna Marina Liberati; Gerardo Musuraca; Anna Lucania; Giuseppina Ricciuti; Lisa Argnani; Pier Luigi Zinzani
Journal:  Oncologist       Date:  2018-04-19

10.  Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Authors:  James N Gerson; Elizabeth Handorf; Diego Villa; Alina S Gerrie; Parv Chapani; Shaoying Li; L Jeffrey Medeiros; Michael I Wang; Jonathon B Cohen; Oscar Calzada; Michael C Churnetski; Brian T Hill; Yazeed Sawalha; Francisco J Hernandez-Ilizaliturri; Shalin Kothari; Julie M Vose; Martin A Bast; Timothy S Fenske; Swapna Narayana Rao Gari; Kami J Maddocks; David Bond; Veronika Bachanova; Bhaskar Kolla; Julio Chavez; Bijal Shah; Frederick Lansigan; Timothy F Burns; Alexandra M Donovan; Nina Wagner-Johnston; Marcus Messmer; Amitkumar Mehta; Jennifer K Anderson; Nishitha Reddy; Alexandra E Kovach; Daniel J Landsburg; Martha Glenn; David J Inwards; Reem Karmali; Jason B Kaplan; Paolo F Caimi; Saurabh Rajguru; Andrew Evens; Andreas Klein; Elvira Umyarova; Bhargavi Pulluri; Jennifer E Amengual; Jennifer K Lue; Catherine Diefenbach; Richard I Fisher; Stefan K Barta
Journal:  J Clin Oncol       Date:  2019-01-07       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.